Predictors of Hepatic Fibrosis in Type 2 Diabetes Patients with Metabolic-Dysfunction-Associated Steatotic Liver Disease
Abstract
:1. Introduction
2. Materials and Methods
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Rinella, M.E.; Lazarus, J.V.; Ratziu, V.; Francque, S.M.; Sanyal, A.J.; Kanwal, F.; Romero, D.; Abdelmalek, M.F.; Anstee, Q.M.; Arab, J.P.; et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Hepatology 2023, 78, 1966–1986. [Google Scholar] [CrossRef] [PubMed]
- Younossi, Z.M.; Golabi, P.; de Avila, L.; Paik, J.M.; Srishord, M.; Fukui, N.; Qiu, Y.; Burns, L.; Afendy, A.; Nader, F. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J. Hepatol. 2019, 71, 793–801. [Google Scholar] [CrossRef] [PubMed]
- Moreira, R.O.; Valerio, C.M.; Villela-Nogueira, C.A.; Cercato, C.; Gerchman, F.; Lottenberg, A.M.; Godoy-Matos, A.F.; Oliveira, R.d.A.; Mello, C.E.B.; Álvares-Da-Silva, M.R.; et al. Brazilian evidence-based guideline for screening, diagnosis, treatment, and follow-up of metabolic dysfunction-associated steatotic liver disease (MASLD) in adult individuals with overweight or obesity: A joint position statement from the Brazilian Society of Endocrinology and Metabolism (SBEM), Brazilian Society of Hepatology (SBH), and Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso). Arch. Endocrinol. Metab. 2015, 67, e230123. [Google Scholar]
- Godoy-Matos, A.F.; Valério, C.M.; Araujo-Neto, J.M.; Silva-Júnior, W.S.; Bertoluci, M.C. 2024 UPDATE: The Brazilian Diabetes Society’s position on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) in people with prediabetes or type 2 diabetes. Diabetol. Metab. Syndr. 2024, 16, 23. [Google Scholar]
- Saeedi, P.; Petersohn, I.; Salpea, P.; Malanda, B.; Karuranga, S.; Unwin, N.; Colagiuri, S.; Guariguata, L.; Motala, A.A.; Ogurtsova, K.; et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9(th) edition. Diabetes Res. Clin. Pract. 2019, 157, 107843. [Google Scholar] [CrossRef]
- Powell, E.E.; Wong, V.W.; Rinella, M.E. Non-alcoholic fatty liver disease. Lancet 2021, 397, 2212–2224. [Google Scholar] [CrossRef]
- Cusi, K. Time to include nonalcoholic steatohepatitis in the management of patients with type 2 diabetes. Diabetes Care 2020, 43, 275–279. [Google Scholar] [CrossRef]
- Kwok, R.; Choi, K.C.; Wong, G.L.; Zhang, Y.; Chan, H.L.; Luk, A.O.; Shu, S.S.-T.; Chan, A.W.-H.; Yeung, M.-W.; Chan, J.C.-N.; et al. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: A prospective cohort study. Gut 2016, 65, 1359–1368. [Google Scholar] [CrossRef]
- Ando, Y.; Jou, J.H. Nonalcoholic fatty liver disease and recent guideline updates. Clin. Liver Dis. 2021, 17, 23–28. [Google Scholar] [CrossRef]
- Zhang, J.Z.; Cai, J.J.; Yu, Y.; She, Z.G.; Li, H. Nonalcoholic fatty liver disease: An update on the diagnosis. Gene Expr. J. Liver Res. 2019, 19, 187–198. [Google Scholar] [CrossRef]
- Leoni, S.; Tovoli, F.; Napoli, L.; Serio, I.; Ferri, S.; Bolondi, L. Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis. World J. Gastroenterol. 2018, 24, 3361–3367. [Google Scholar] [CrossRef] [PubMed]
- van Kleef, L.A.; Francque, S.M.; Prieto-Ortiz, J.E.; Sonneveld, M.J.; Sanchez-Luque, C.B.; Prieto-Ortiz, R.G.; Kwanten, W.J.; Vonghia, L.; Verrijken, A.; De Block, C.; et al. Metabolic dysfunction–associated fibrosis 5 (MAF-5) score predicts liver fibrosis risk and outcome in the general population with metabolic dysfunction. Gastroenterology 2024, 167, 357–367.e9. [Google Scholar] [CrossRef] [PubMed]
- Bota, S.; Herkner, H.; Sporea, I.; Salzl, P.; Sirli, R.; Neghina, A.M.; Peck-Radosavljevic, M. Meta-analysis: ARFI elastography versus transient elastography for the evaluation of liver fibrosis. Liver Int. 2013, 33, 1138–1147. [Google Scholar] [CrossRef] [PubMed]
- Chalasani, N.; Younossi, Z.; Lavine, J.E.; Diehl, A.M.; Brunt, E.M.; Cusi, K.; Charlton, M.; Sanyal, A.J. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012, 55, 2005–2023. [Google Scholar] [CrossRef] [PubMed]
- López Tórrez, S.M.; Ayala, C.O.; Ruggiro, P.B.; Costa, C.A.D.; Wagner, M.B.; Padoin, A.V.; Mattiello, R. Accuracy of prognostic serological biomarkers in predicting the severity of liver fibrosis in people with steatotic liver disease associated with metabolic dysfunction: A meta-analysis of more than 40,000 participants. Front. Nutr. 2024, 11, 1284509. [Google Scholar] [CrossRef]
- Archer, A.J.; Belfield, K.J.; Orr, J.G.; Gordon, F.H.; Abeysekera, K.W. EASL clinical practice guidelines: Non-invasive liver tests for evaluation of liver disease severity and prognosis. Front. Gastroenterol. 2022, 13, 436–439. [Google Scholar] [CrossRef]
- Szczepaniak, L.S.; Nurenberg, P.; Leonard, D.; Browning, J.D.; Reingold, J.S.; Grundy, S.; Hobbs, H.H.; Dobbins, R.L. Magnetic resonance spectroscopy to measure hepatic triglyceride content: Prevalence of hepatic steatosis in the general population. Am. J. Physiol. Endocrinol. Metab. 2005, 288, E462–E468. [Google Scholar] [CrossRef]
- Friedewald, W.T.; Levy, R.I.; Fredrickson, D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 1972, 18, 499–502. [Google Scholar] [CrossRef]
- Yang, S.; Cheng, J.; Zhang, R.; Sun, H.; Zhang, H.; Lyu, S.; Duan, W. Metabolic dysfunction-associated fatty liver disease and liver fibrosis: Prevalence and associated factors in the middle-aged and older US population. Hepatol. Res. 2022, 52, 176–186. [Google Scholar] [CrossRef]
- Angulo, P.; Hui, J.M.; Marchesini, G.; Bugianesi, E.; George, J.; Farrell, G.C.; Enders, F.; Saksena, S.; Burt, A.D.; Bida, J.P.; et al. The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007, 45, 846–854. [Google Scholar] [CrossRef]
- Rinella, M.E.; Sookoian, S. From NAFLD to MASLD: Updated naming and diagnosis criteria for fatty liver disease. J. Lipid Res. 2024, 65, 100485. [Google Scholar] [CrossRef] [PubMed]
- Silva Júnior, W.S.; Valério, C.M.; Araujo-Neto, J.M.; Godoy-Matos, A.F. Manejo da Doença Hepática Esteatótica Metabólica (DHEM) no Diabetes Tipo 2 e Pré Diabetes. Dir. Of. Soc. Bras. Diabetes 2024, 1–35. [Google Scholar] [CrossRef]
- Alberti, K.G.; Eckel, R.H.; Grundy, S.M.; Zimmet, P.Z.; Cleeman, J.I.; Donato, K.A.; Fruchart, J.-C.; James, W.P.T.; Loria, C.M.; Smith, S.C., Jr. Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120, 1640–1645. [Google Scholar] [PubMed]
- Younossi, Z.M.; Gramlich, T.; Matteoni, C.A.; Boparai, N.; McCullough, A.J. Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin. Gastroenterol. Hepatol. 2004, 2, 262–265. [Google Scholar] [CrossRef]
- Kivimäki, M.; Strandberg, T.; Pentti, J.; Nyberg, S.T.; Frank, P.; Jokela, M.; Ervasti, J.; Suominen, S.B.; Vahtera, J.; Sipilä, P.N.; et al. Body-mass index and risk of obesity-related complex multimorbidity: An observational multicohort study. Lancet Diab. Endocrinol. 2022, 10, 253–263. [Google Scholar] [CrossRef]
- Miao, L.; Targher, G.; Byrne, C.D.; Cao, Y.Y.; Zheng, M.H. Current status and future trends of the global burden of MASLD. Trends Endocrinol. Metab. 2024, 35, 400–413. [Google Scholar] [CrossRef]
- Quek, J.; Chan, K.E.; Wong, Z.Y.; Tan, C.; Tan, B.; Lim, W.H.; Tan, D.J.H.; Tang, A.S.P.; Tay, P.; Xiao, J.; et al. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: A systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 2023, 8, 20–30. [Google Scholar] [CrossRef]
- Browning, J.D.; Szczepaniak, L.S.; Dobbins, R.; Nuremberg, P.; Horton, J.D.; Cohen, J.C.; Grundy, S.M.; Hobbs, H.H. Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity. Hepatology 2004, 40, 1387–1395. [Google Scholar] [CrossRef]
- Mózes, F.E.; Lee, J.A.; Selvaraj, E.A.; Jayaswal, A.N.A.; Trauner, M.; Boursier, J.; Fournier, C.; Staufer, K.; Stauber, R.E.; Bugianesi, E.; et al. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: An individual patient data meta-analysis. Gut 2022, 71, 1006–1019. [Google Scholar] [CrossRef]
- Corrêa, M.M.; Facchini, L.A.; Thumé, E.; Oliveira, E.R.A.D.; Tomasi, E. The ability of waist-to-height ratio to identify health risks. Rev. Saude Publica 2019, 53, 66. [Google Scholar] [CrossRef]
- Kojima, S.I.; Watanabe, N.; Numata, M.; Ogawa, T.; Matsuzaki, S. Increase in the prevalence of fatty liver in Japan over the past 12 years: Analysis of clinical background. J. Gastroenterol. 2003, 38, 954–961. [Google Scholar] [CrossRef] [PubMed]
- Lee, C.G.; Carr, M.C.; Murdoch, S.J.; Mitchell, E.; Woods, N.F.; Wener, M.H. Adipokines, inflammation, and visceral adiposity across the menopausal transition: A prospective study. J. Clin. Endocrinol. Metab. 2009, 94, 1104–1110. [Google Scholar] [CrossRef] [PubMed]
- Gutierrez-Grobe, Y.; Ponciano-Rodríguez, G.; Ramos, M.H.; Uribe, M.; Méndez-Sánchez, N. Prevalence of non-alcoholic fatty liver disease in premenopausal, postmenopausal, and polycystic ovary syndrome women: The role of estrogens. Ann. Hepatol. 2010, 9, 402–409. [Google Scholar] [CrossRef] [PubMed]
- Whitsett, M.; VanWagner, L.B. Physical activity as a treatment of non-alcoholic fatty liver disease: A systematic review. World J. Hepatol. 2015, 7, 2041. [Google Scholar] [CrossRef]
- Le, M.H.; Yeo, Y.H.; Li, X.; Li, J.; Zou, B.; Wu, Y.; Ye, Q.; Huang, D.Q.; Zhao, C.; Zhang, J.; et al. 2019 Global NAFLD prevalence: A systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 2022, 20, 2809–2817.e28. [Google Scholar] [CrossRef]
- Guthold, R.; Stevens, G.A.; Riley, L.M.; Bull, F.C. Worldwide trends in insufficient physical activity from 2001 to 2016: A pooled analysis of 358 population-based surveys with 1.9 million participants. Lancet Glob. Health 2018, 6, e1077–e1086. [Google Scholar] [CrossRef]
- Amernia, B.; Moosavy, S.H.; Banookh, F.; Zoghi, G. FIB-4, APRI, and AST/ALT ratio compared to FibroScan for the assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease in Bandar Abbas, Iran. BMC Gastroenterol. 2021, 21, 453. [Google Scholar] [CrossRef]
- Ucar, F.; Sezer, S.; Ginis, Z.; Ozturk, G.; Albayrak, A.; Basar, O.; Fuat, E.; Sahinc, C.; Osmanc, Y.; Ferah, A.; et al. APRI, the FiB-4 score, and Forn’s index have noninvasive diagnostic value for liver fibrosis in patients with chronic hepatitis B. Eur. J. Gastroenterol. Hepatol. 2013, 25, 1076–1081. [Google Scholar] [CrossRef]
- Peleg, N.; Issachar, A.; Sneh-Arbib, O.; Shlomai, A. AST to Platelet Ratio Index and fibrosis 4 calculator scores for non-invasive assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease. Dig. Liver Dis. 2017, 49, 1133–1138. [Google Scholar] [CrossRef]
- Park, H.; Yoon, E.L.; Ito, T.; Jo, A.J.; Kim, M.; Lee, J.; Kim, H.-L.; Arai, T.; Atsukawa, M.; Kawanaka, M.; et al. Diagnostic performance of the Fibrosis-4 index and Nonalcoholic Fatty Liver Disease Fibrosis Score in lean adults with nonalcoholic fatty liver disease. JAMA Netw. Open 2023, 6, e2329568. [Google Scholar] [CrossRef]
- Roulot, D.; Roudot-Thoraval, F.; Nkontchou, G.; Kouacou, N.; Costes, J.L.; Elourimi, G.; Le Clesiau, H.; Ziol, M.; Beaugrand, M. Concomitant screening for liver fibrosis and steatosis in French type 2 diabetic patients using Fibroscan. Liver Int. 2017, 37, 1897–1906. [Google Scholar] [CrossRef] [PubMed]
- Fallatah, H.I.; Akbar, H.O.; Fallatah, A.M. Fibroscan compared to FIB-4, APRI, and AST/ALT ratio for assessment of liver fibrosis in saudi patients with nonalcoholic fatty liver disease. Hepat. Mon. 2016, 16, e38346. [Google Scholar] [CrossRef] [PubMed]
- Huang, C.F.; Liang, P.C.; Wang, C.W.; Jang, T.Y.; Hsu, P.Y.; Tsai, P.C.; Wei, Y.-J.; Yeh, M.-L.; Hsieh, M.-Y.; Lin, Y.-H.; et al. Performance of non-invasive seromarkers in predicting liver fibrosis among MAFLD patients with or without viral hepatitis. Kaohsiung J. Med. Sci. 2024, 40, 374–383. [Google Scholar] [CrossRef] [PubMed]
Variables | Diagnosis of Liver Fibrosis by Transient Elastography | p | |||
---|---|---|---|---|---|
No (<F2) (n = 176, 73.3%) | Yes (≥F2) (n = 64, 26.7%) | ||||
Sex, n (%) | 0.002 * | ||||
Male | 73 | (41.5) | 13 | (20.3) | |
Female | 103 | (58.5) | 51 | (79.7) | |
Age (in years), mean ± SD | 60.3 | ±9.9 | 61.5 | ±8.6 | 0.606 |
Age group, n (%) | 0.390 | ||||
Up to 40 years old | 8 | (4.5) | 0 | (0) | |
41 to 50 years old | 18 | (10.2) | 7 | (10.9) | |
51 to 60 years old | 55 | (31.3) | 21 | (32.8) | |
Over 60 years old | 95 | (54.0) | 36 | (56.3) | |
Self-reported skin color/race, n (%) | 0.842 | ||||
White | 25 | (14.2) | 10 | (15.6) | |
Black | 36 | (20.5) | 11 | (17.2) | |
Brown | 115 | (65.3) | 43 | (67.2) | |
Smoking, n (%) | 0.899 | ||||
Never | 101 | (57.4) | 35 | (54.7) | |
Former | 73 | (41.5) | 28 | (43.8) | |
Current | 2 | (1.1) | 1 | (1.5) | |
Physical activity | 0.336 | ||||
Inactive | 63 | (35.8) | 30 | (46.9) | |
Moderately inactive | 81 | (46.0) | 27 | (42.2) | |
Moderately active | 28 | (15.9) | 7 | (10.9) | |
Highly active | 4 | (2.3) | 0 | (0) | |
Dietary adherence | 0.250 | ||||
No (<80%) | 101 | (57.4) | 42 | (65.6) | |
Yes (≥80%) | 75 | (42.6) | 22 | (34.4) | |
Time since type 2 diabetes diagnosis (in years), mean ± SD | 12.5 | ±8.9 | 11.9 | ±9.3 | 0.637 |
Comorbidities | |||||
Arterial hypertension | 125 | (71.0) | 45 | (70.3) | 0.915 |
Dyslipidaemia | 163 | (92.6) | 59 | (92.2) | 0.912 |
Obesity 1 | 60 | (34.1) | 34 | (53.1) | 0.008 * |
Neuropathy | 69 | (39.2) | 23 | (35.9) | 0.645 |
Thyroid dysfunction | 43 | (24.4) | 17 | (26.6) | 0.736 |
Osteopenia/osteoporosis | 32 | (18.2) | 15 | (23.4) | 0.364 |
Retinopathy | 31 | (17.6) | 8 | (12.5) | 0.342 |
Chronic kidney disease | 23 | (13.1) | 4 | (6.3) | 0.170 |
Coronary artery disease | 17 | (9.7) | 6 | (9.4) | 0.947 |
Variables | Diagnosis of Liver Fibrosis by Transient Elastography | p | |||
---|---|---|---|---|---|
No (<F2) | Yes (≥F2) | ||||
Mean | ±SD | Mean | ±SD | ||
Anthropometric data (male group) | |||||
BMI (in kg/m2) | 29.7 | ±4.3 | 33.9 | ±6.6 | 0.027 * |
NC (in cm) | 40.1 | ±2.7 | 41.7 | ±3.2 | 0.085 |
WC (in cm) | 104.4 | ±11.3 | 112.2 | ±15.3 | 0.105 |
HC (in cm) | 101.2 | ±8.1 | 106.4 | ±8.7 | 0.049 * |
Waist-to-hip ratio | 1.03 | ±0.07 | 1.05 | ±0.07 | 0.400 |
Waist-to-height ratio | 0.63 | ±0.07 | 0.68 | ±0.09 | 0.130 |
Anthropometric data (female group) | |||||
BMI (in kg/m2) | 31.1 | ±4.7 | 33.3 | ±6.7 | 0.096 |
NC (in cm) | 35.3 | ±2.5 | 36.0 | ±2.9 | 0.299 |
WC (in cm) | 100.6 | ±9.7 | 104.2 | ±12.8 | 0.152 |
HC (in cm) | 109.7 | ±10.6 | 108.9 | ±13.5 | 0.231 |
Waist-to-hip ratio | 0.95 | ±0.05 | 0.95 | ±0.05 | 0.489 |
Waist-to-height ratio | 0.66 | ±0.06 | 0.69 | ±0.08 | 0.173 |
Serum data | |||||
Fasting blood glucose (mg/dL) | 154 | ±69 | 147 | ±59 | 0.779 |
HbA1c (%) | 8.2 | ±1.8 | 8.1 | ±1.9 | 0.734 |
Insulin (µIU/L) | 22.5 | ±31.4 | 20.8 | ±18.4 | 0.199 |
HOMA-IR | 4.3 | ±4.2 | 4.7 | ±3.2 | 0.198 |
α-fetoprotein (ng/dL) | 2.0 | ±1.1 | 2.3 | ±1.2 | 0.027 * |
Ferritin (ng/dL) | 152 | ±158 | 167 | ±169 | 0.418 |
GGT (U/L) | 47.3 | ±55.7 | 84.9 | ±150.5 | <0.001 * |
Albumin (mg/dL) | 4.4 | ±0.3 | 4.3 | ±0.2 | 0.150 |
Hemoglobin (g/dL) | 13.6 | ±1.5 | 13.4 | ±1.2 | 0.357 |
Platelet count (×109/L) | 262 | ±85 | 245 | ±87 | 0.117 |
Total cholesterol (mg/dL) | 163 | ±44 | 158 | ±41 | 0.737 |
HDL cholesterol (mg/dL) | 43.9 | ±10.6 | 47.1 | ±10.6 | 0.039 * |
LDL cholesterol (mg/dL) | 85.4 | ±37.3 | 82.6 | ±35.8 | 0.790 |
VLDL cholesterol (mg/dL) | 33.7 | ±19.1 | 29.6 | ±13.4 | 0.240 |
Non-HDL cholesterol (mg/dL) | 116 | ±42 | 110 | ±38 | 0.519 |
TG (mg/dL) | 169 | ±99 | 147 | ±67 | 0.243 |
AST (U/L) | 21.1 | ±11.4 | 28.9 | ±18.3 | <0.001 * |
ALT (U/L) | 23.4 | ±12.6 | 29.5 | ±18.0 | 0.014 * |
Variables | Diagnosis of Liver Fibrosis by Transient Elastography | p | |||
---|---|---|---|---|---|
No (<F2) | Yes (≥F2) | ||||
n | (%) | n | (%) | ||
CAP score | 0.007 * | ||||
No steatosis (S0) | 16 | (9.1) | 0 | (0) | |
Mild steatosis (S1) | 37 | (21.1) | 7 | (10.9) | |
Moderate steatosis (S2) | 57 | (32.7) | 22 | (34.4) | |
Severe steatosis (S3) | 65 | (37.1) | 35 | (54.7) | |
FIB-4 score | <0.001 * | ||||
Lower cut-off value | 127 | (72.2) | 31 | (48.4) | |
Higher cut-off value | 49 | (27.8) | 33 | (51.6) | |
NAFLD fibrosis score | 0.600 | ||||
Less than −1.455 (F0–F2) | 26 | (14.8) | 9 | (14.1) | |
Between −1.455 and 0.675 (Undefined) | 80 | (45.5) | 25 | (39.1) | |
Above 0.675 (F3–F4) | 70 | (39.7) | 30 | (46.8) | |
MAF-5 score | 0.037 * | ||||
<0 | 31 | (17.6) | 4 | (6.3) | |
0–1 | 36 | (20.5) | 10 | (15.6) | |
>1 | 109 | (61.9) | 50 | (78.1) |
Scores | Cut-Off | Sensitivity | (95% CI) | Specificity | (95% CI) |
---|---|---|---|---|---|
FIB-4 | >1.3 | 53.8% | (41.9–65.4) | 68.8% | (61.6–75.1) |
>1.45 | 44.6% | (33.2–56.7) | 76.7% | (69.9–82.3) | |
>2.0 | 27.7% | (18.3–39.6) | 96.0% | (92.0–98.1) | |
>2.67 | 12.3% | (6.4–22.5) | 98.3% | (95.1–99.5) | |
>3.25 | 7.7% | (3.3–16.8) | 98.9% | (96.0–99.8) | |
NAFLD | >−1.455 | 84.6% | (73.9–91.4) | 13.6% | (9.3–19.5) |
>0.675 | 46.2% | (34.6–58.1) | 59.7% | (52.3–66.7) | |
MAF-5 | >0 | 92.2% | (83.0–96.6) | 17.6% | (12.7–23.9) |
>1 | 78.1% | (66.7–86.5) | 38.1% | (32.2–45.4) |
Factors | Adjusted OR | (95% CI) | p |
---|---|---|---|
Age | 1.02 | (0.98–1.05) | 0.197 |
Female | 2.69 | (1.35–5.35) | 0.005 * |
Obesity | 2.23 | (1.22–4.07) | 0.009 * |
High α-fetoprotein | 1.26 | (0.58–2.71) | 0.549 |
High GGT | 3.78 | (2.01–7.14) | <0.001 * |
Low HDL | 0.74 | (0.39–1.41) | 0.372 |
High AST | 6.07 | (2.27–16.2) | <0.001 * |
High ALT | 3.83 | (1.80–8.11) | <0.001 * |
Independent Variables | Collinearity Statistics | |
---|---|---|
VIF | Tolerance | |
Age | 1.06 | 0.946 |
Female | 1.06 | 0.947 |
Obesity | 1.11 | 0.901 |
High α-fetoprotein | 1.03 | 0.973 |
High GGT | 1.29 | 0.773 |
Low HDL | 1.05 | 0.952 |
High AST | 1.45 | 0.691 |
High ALT | 1.56 | 0.640 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
de Abreu, J.D.M.F.; Azulay, R.S.; Rodrigues, V.; de Abreu, S.L.L.; da Glória Tavares, M.; Pinheiro, F.C.M.; de Oliveira Neto, C.P.; Andrade, C.; Facundo, A.; Sá, A.G.; et al. Predictors of Hepatic Fibrosis in Type 2 Diabetes Patients with Metabolic-Dysfunction-Associated Steatotic Liver Disease. Biomedicines 2024, 12, 2542. https://doi.org/10.3390/biomedicines12112542
de Abreu JDMF, Azulay RS, Rodrigues V, de Abreu SLL, da Glória Tavares M, Pinheiro FCM, de Oliveira Neto CP, Andrade C, Facundo A, Sá AG, et al. Predictors of Hepatic Fibrosis in Type 2 Diabetes Patients with Metabolic-Dysfunction-Associated Steatotic Liver Disease. Biomedicines. 2024; 12(11):2542. https://doi.org/10.3390/biomedicines12112542
Chicago/Turabian Stylede Abreu, Joana D’Arc Matos França, Rossana Sousa Azulay, Vandilson Rodrigues, Sterffeson Lamare Lucena de Abreu, Maria da Glória Tavares, Flávia Coelho Mohana Pinheiro, Clariano Pires de Oliveira Neto, Caio Andrade, Alexandre Facundo, Adriana Guimarães Sá, and et al. 2024. "Predictors of Hepatic Fibrosis in Type 2 Diabetes Patients with Metabolic-Dysfunction-Associated Steatotic Liver Disease" Biomedicines 12, no. 11: 2542. https://doi.org/10.3390/biomedicines12112542
APA Stylede Abreu, J. D. M. F., Azulay, R. S., Rodrigues, V., de Abreu, S. L. L., da Glória Tavares, M., Pinheiro, F. C. M., de Oliveira Neto, C. P., Andrade, C., Facundo, A., Sá, A. G., Azevedo, P. R., Almeida, A. G. P. d., Costa, D. C. d. A., Castro, R. S., Magalhães, M., Nascimento, G. C., Faria, M. d. S., & Ferreira, A. d. S. P. (2024). Predictors of Hepatic Fibrosis in Type 2 Diabetes Patients with Metabolic-Dysfunction-Associated Steatotic Liver Disease. Biomedicines, 12(11), 2542. https://doi.org/10.3390/biomedicines12112542